文献速递乳腺癌

年龄对TEAM试验辅助内分泌治疗后10年乳腺癌死亡及竞争性死因的影响

Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial.
PubMed 文献 · Eur J Cancer · 2018-06-06

TEAM试验纳入2001—2006年绝经后激素受体阳性乳腺癌患者,按诊断年龄<65岁(n=3369)、65-74岁(n=1896)、≥75岁(n=854)分组,中位随访9.8年,采用竞争风险分析评估乳腺癌死亡与其他原因死亡。结果显示乳腺癌累积死亡率随年龄升高(<65岁11.7%、65-74岁12.7%、≥75岁15.6%),单因素竞争风险风险比随年龄增加(≥75岁sHR 1.30,95%CI 1.06-1.58,P=0.013),多因素校正肿瘤与治疗特征后未达显著(≥75岁sHR 1.18,95%CI 0.94-1.48,P=0.055)。

要点

  • ≥75岁患者10年乳腺癌累积死亡率为15.6%,高于<65岁的11.7%。
  • 单因素分析中年龄与乳腺癌死亡风险升高相关,多因素校正后未达显著。
  • 老年患者其他原因死亡升高不足以抵消乳腺癌死亡风险,需平衡治疗不足与过度治疗。

核心结论

  • 诊断后10年,单因素分析中诊断年龄越大乳腺癌死亡率越高,但多因素分析未达显著。
  • 老年患者其他原因死亡升高并未实质抵消其乳腺癌死亡风险。
  • 需改善老年乳腺癌患者治疗不足与过度治疗之间的平衡。

研究设计与样本

  • TEAM试验为辅助内分泌治疗研究,纳入2001—2006年绝经后激素受体阳性乳腺癌患者。
  • 按诊断年龄分为<65岁(n=3369)、65-74岁(n=1896)、≥75岁(n=854)三组。
  • 中位随访9.8年(四分位距8.0-10.3),以其他原因死亡为竞争事件行竞争风险分析。

主要发现

  • 乳腺癌累积死亡率随年龄升高:<65岁11.7%(95%CI 10.2-13.2)、65-74岁12.7%(11.2-14.2)、≥75岁15.6%(13.1-18.0)。
  • 单因素竞争风险亚分布风险比随年龄升高:65-74岁sHR 1.08(95%CI 0.92-1.27)、≥75岁sHR 1.30(95%CI 1.06-1.58),P=0.013。
  • 多因素校正肿瘤与治疗特征后sHR仍随年龄升高但未达显著:65-74岁sHR 1.11(95%CI 0.94-1.31)、≥75岁sHR 1.18(95%CI 0.94-1.48),P=0.055。

关键数值与推荐

  • 乳腺癌死亡累积发生率:<65岁11.7%(95%CI 10.2-13.2)、65-74岁12.7%(11.2-14.2)、≥75岁15.6%(13.1-18.0)。
  • 单因素亚分布风险比:65-74岁sHR 1.08(95%CI 0.92-1.27)、≥75岁sHR 1.30(95%CI 1.06-1.58),P=0.013。
  • 多因素亚分布风险比:65-74岁sHR 1.11(95%CI 0.94-1.31)、≥75岁sHR 1.18(95%CI 0.94-1.48),P=0.055。

临床怎么用

  • 对≥75岁激素受体阳性乳腺癌患者,应重视其长期乳腺癌死亡风险而非仅关注其他原因死亡。
  • 治疗决策需权衡治疗不足与过度治疗,避免仅因年龄因素降级治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Due to increasing life expectancy, patients with breast cancer remain at risk of dying due to breast cancer over a long time. This study aims to assess the impact of age on breast cancer mortality and other cause mortality 10 years after diagnosis. METHODS: Postmenopausal patients with hormone-receptor positive breast cancer were included in the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial between 2001 and 2006. Age at diagnosis was categorised as <65 years (n = 3369), 65-74 years (n = 1896) and ≥75 years (n = 854). Breast cancer mortality was assessed considering other cause mortality as competing event using competing risk analysis. RESULTS: After a median follow-up of 9.8 years (interquartile range 8.0-10.3), cumulative incidence of breast cancer mortality increased with increasing age (age <65 years, 11.7% [95% confidence interval {CI}: 10.2-13.2]; 65-74 years, 12.7% (11.2-14.2) and ≥75 years, 15.6% (13.1-18.0)). Univariate subdistribution hazard ratio (sHR) increased with increasing age (age: 65-74 years, sHR: 1.08, 95% CI: 0.92-1.27 and ≥75 years sHR: 1.30, 95% CI: 1.06-1.58, P = 0.013). Multivariable sHR adjusted for tumour and treatment characteristics increased with age but did not reach significance (age 65-74 years, sHR: 1.11, 95% CI: 0.94-1.31; ≥75 years, sHR: 1.18, 95% CI: 0.94-1.48, P = 0.055). CONCLUSION: Ten years after diagnosis, older age at diagnosis is associated with increasing breast cancer mortality in univariate analysis, but it did not reach significance in multivariable analysis. This is not outweighed by a substantially higher other cause mortality with older age. This underlines the need to improve the balance between undertreatment and overtreatment in older patients with breast cancer. The trial was registered in International Trial Databases (ClinicalTrials.govNCT00279448, NCT00032136, and NCT00036270; the Netherlands Trial Registry NTR267).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Derks MGM, Bastiaannet E, van de Water W, et al. Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. Eur J Cancer. 2018. PMID: 29885375. doi:10.1016/j.ejca.2018.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。